Cargando…
Pomalidomide- and dexamethasone-based regimens in the treatment of refractory/relapsed multiple myeloma
Pomalidomide is a potent immunomodulatory agent that is currently a standard of care backbone for the treatment of multiple myeloma (MM) patients in the relapsed/refractory setting after exposure to lenalidomide and a proteasome inhibitor. The present review addresses current knowledge regarding the...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
SAGE Publications
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9109494/ https://www.ncbi.nlm.nih.gov/pubmed/35585966 http://dx.doi.org/10.1177/20406207221090089 |